Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$21.55M+397.09%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Cordonnier
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 127
- Beta
- 1.97
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 6.33
Financials
Revenue
$21.55M+397.1%Net Income
$-12.24MEBITDA
$-11.80MFree Cash Flow
$-8.96MEPS (diluted)
$-0.45Shares Outstanding (diluted)
27.30M+3.0%Operating Expenses
$29.37MCash & Debt
$80.21MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $50.51M | $-29.63M | $-2.12 |
| 2024 | $27.16M | $-24.26M | $-1.50 |
| 2023 | $13.78M | $-18.90M | $-4.25 |
Valuation
CARLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-23.08%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·6d ago·Neutral
Carlsmed to Participate in Upcoming Investor Conferences CARLSBAD, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that management will participate in the following investor conferences:
View source ↗ - Newszacks.com·12d ago·Negative
Carlsmed, Inc. (CARL) Reports Q3 Loss, Tops Revenue Estimates Carlsmed, Inc. (CARL) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.4 per share a year ago.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026 CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2026 financial results after market close on Tuesday, November 10, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacifi…
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System CARLSBAD, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior System at the North American Spine Society's 41st Annual Meeting (NASS) in San Antonio, TX. The launch follows a limited market evaluation that commenced in February 2026, with the first in human procedure completed on February 10, 2026.
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
Carlsmed Appoints Tony Jarc as Chief Product and AI Officer CARLSBAD, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Tony Jarc, Ph.D. has been appointed to the newly-created position of Chief Product and AI Officer, effective immediately. Dr. Jarc will lead the development and commercialization of the Company's next generation techn…
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Carlsmed Appoints Richard Heppenstall as Chief Financial Officer CARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been appointed Chief Financial Officer, effective immediately.
View source ↗ - Newsglobenewswire.com·68d ago·Positive
Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical CARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” ), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today filed a patent infringement lawsuit against DeGen Medical, Inc. (“DeGen”) in the United States District Court for the District of South Carolina Florence Division.
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $-0.41 per share
Typical surprise +11.1% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.34 vs $-0.39beat
- Wed, Aug 5$-0.39 vs $-0.40beat
- Tue, May 5$-0.32 vs $-0.43beat
- Wed, Feb 25$-0.32 vs $-0.43beat
- Thu, Nov 6$-0.40 vs $-0.45beat
- Thu, Aug 28$-1.47 vs $-1.52beat
Estimates and results for CARL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CARL officers and directors.
- Bought
- $51.1m
- Sold
- $2.7m
7 trades
5 trades
- Bertolini Jeffreysold
- Bertolini Jeffreysold
- Bertolini Jeffreysold
- Bertolini Jeffreysold
- Cordonnier Michaelsold
- Presidio Management Group Xii, L.l.c.bought
- B Capital Group Management, L.p.bought
- Sidow Kevinbought
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CARL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
